Why Preclinical PDX Data Cuts Oncology Trial Failures
Cancer drug development is hard. Most new drugs that enter human trials never reach patients, and each failure costs years of work and millions of dollars. It also means patients wait longer for better treatments.
Many of these failures share one root cause. The early lab data did not predict how the drug would work in real people. Simple models can make a drug look strong in the lab, and then it falls short in the clinic.
Better preclinical data can help close this gap. Patient-derived xenograft models are one of the best tools for the job. They let teams test drugs on real human tumors before the first patient is dosed.
When these models come with clinical data from the original patient, they become even more useful. In this article, we explain how PDX models work, why they predict patient response better than many older models, and how in vivo pharmacology data can help oncology teams avoid costly Phase I and Phase II failures.
The High Cost of Failed Oncology Trials
Oncology has one of the lowest success rates in drug development. A large MIT study of clinical trial data found that only 3.4% of cancer drugs that entered testing went on to approval. That rate was far lower than in most other disease areas.
Every failed trial has a high price. Teams spend years on research, trial sites, and patient enrollment. When a drug fails in Phase II, most of that money is gone.
Patients who joined the trial may also have missed other options. For small biotech companies, one failure can end the business.
That’s why making better choices before human trials start is so important. Strong preclinical data gives teams a clearer view of which drugs deserve the next step.
Why Most Cancer Drugs Fail
Drugs fail for several reasons. A 2022 review in Acta Pharmaceutica Sinica B looked at why about 90% of clinical drug candidates fail. It found that 40% to 50% fail because they don’t work well enough in patients.
Another 30% fail due to side effects that can’t be managed. Lack of efficacy is the biggest problem. In many cases, the drug looked promising in early lab tests.
But those tests used models that did not reflect real human tumors, and this points to a clear lesson. If preclinical models predicted efficacy better, fewer weak drugs would reach the clinic. The drugs that did move forward would also have a better chance of success.
What Are PDX Models?
A PDX model starts with a piece of a real patient’s tumor. Scientists implant this tissue into a mouse with a weak immune system. The tumor then grows inside the mouse, keeping many features of the original cancer.
Researchers can then test drugs on these tumors. They can see whether a drug shrinks the tumor, slows its growth, or has no effect. Because the tumor came from a real person, the results often reflect how a patient might respond.
Well-built patient-derived xenograft (PDX) models capture the wide range of cancers seen in the clinic. Teams can test a drug across many tumor types and genetic profiles before starting a human trial.
Why Clinical Annotation Matters
A PDX model is more useful when it comes with details about the patient. This is called clinical annotation. It may include the patient’s diagnosis, past treatments, how they responded, and the tumor’s genetic profile.
The National Cancer Institute’s Patient-Derived Models Repository links each model to patient history, including treatment and outcome data. This helps researchers choose models that are likely to respond, or not respond, to a certain drug.
Annotation turns a mouse study into something closer to a small clinical study, and teams can ask better questions. For example, did tumors from patients who failed a certain therapy also resist the new drug? Answers like this help shape trial design.
How PDX Models Compare to Cell Lines
For decades, cancer research relied on cell lines. These are tumor cells grown in plastic dishes, often for many years.
They are cheap and easy to use. But they have major limits.
Over time, cell lines change. They pick up new mutations and lose features of the original tumor. They also lack the structure of a real tumor, such as blood vessels and support tissue.
PDX models solve many of these problems. Key differences include:
- Tumors keep original patient features
- Models show real tumor diversity
- Growth happens inside a living body
- Results reflect complex drug exposure
Cell lines still have a role in early screening. But PDX models offer a more realistic test before moving into human trials.
How Well PDX Results Match Patient Results
The real test of any model is whether it predicts what happens in patients. Here, PDX models have a strong record.
One study published in Annals of Oncology compared PDX results with outcomes in the patients who donated the tumors. The researchers found that PDX responses matched patient responses in 87% of cases. This held across many different tumor types and treatments.
No model is perfect. But a match rate this high gives oncology teams real confidence. When a drug fails in a well-designed PDX study, there’s a good chance it would fail in patients, too, and that early signal can save years of wasted effort.
What In Vivo Pharmacology Data Adds
In vivo means “in a living body.” In vivo pharmacology studies show how a drug acts inside a living animal, not just in a dish.
These studies answer key questions. How much of the drug reaches the tumor? How long does it stay active?
Does it hit its target? What side effects appear at different doses?
When teams combine this data with PDX results, they get a fuller picture. They can link drug levels in the blood to changes in tumor growth, and this helps them understand not just whether a drug works, but how and why. That knowledge is vital when planning the first human trial.
Finding the Right Patients Early
Many cancer drugs only work in certain patients. For example, a drug may only help people whose tumors carry a specific mutation. If a trial enrolls the wrong patients, even a good drug can look like a failure.
PDX models help solve this problem. By testing a drug across many models with known genetic profiles, teams can see which tumors respond. They can then look for biomarkers, which are signs that predict response.
These biomarkers can guide who enrolls in a trial. Trials that select patients this way often have a better chance of success. They may also need fewer patients to show a clear benefit.
Testing Drug Combinations Before the Clinic
Many modern cancer treatments use two or more drugs together. But testing every possible combination in humans would take decades. It would also put patients at risk.
PDX models offer a faster path. Teams can test several combinations at once across a panel of tumors. They can see which pairs work better together and which offer no added benefit.
This approach helps teams focus on the most promising options. It also reveals combinations that may cause too much harm. By the time a combination reaches a clinical trial, there’s strong evidence behind it.
Running Mouse Clinical Trials
A mouse clinical trial uses many PDX models to mimic a human trial. Instead of testing one drug on one model, teams test it across a large group of tumors. This shows how a drug might perform across a varied patient population.
In 2015, Novartis researchers tested more than 60 treatments across hundreds of PDX models. They used a simple design: one mouse, one tumor, one treatment. The results matched known human trial outcomes.
The study also pointed to a promising new drug combination for melanoma. This kind of study gives teams a preview of response rates before human testing. It can flag drugs that only work in a small group of tumors.
Understanding Drug Resistance
Cancer often finds ways to resist treatment. A drug may work at first, then stop working as the tumor adapts. This is a major reason why many patients relapse.
PDX models help researchers study resistance before it shows up in trials. Teams can treat tumors over time and watch for regrowth. They can then study what changed in the resistant tumors.
Models made from patients who already failed a treatment are also useful. They let teams test whether a new drug can overcome known resistance. This information helps position a drug for the right patients, such as those who need a next-line option.
Setting Better Doses for Phase I
Phase I trials focus on safety and dosing. Choosing a good starting dose is critical. Start too low, and patients may get no benefit.
Start too high, and they may face serious side effects. Preclinical pharmacology data helps guide these choices. Studies in animals show how drug levels relate to tumor response and side effects.
Teams can use this to estimate a dose range that is both safe and likely to work. Better dose planning can shorten Phase I trials. It can also lower the risk of moving forward with a dose that is too weak to show benefit in Phase II.
Stopping Weak Drugs Sooner
Not every drug deserves to move forward. One of the most valuable things preclinical data can do is help teams say no early.
Stopping a weak drug before human trials saves money and time. It also frees up resources for stronger candidates. This approach is often called “fail fast, fail cheap.”
PDX studies give clear signals. If a drug shows little effect across a broad panel of tumors, that’s a warning sign.
Teams can then decide to drop the drug, change its design, or focus on a smaller group of patients. Each choice is better than a costly Phase II failure.
Building a Stronger Case for Investors and Regulators
Strong preclinical data does more than guide science. It also helps teams make their case to others.
Investors want proof that a drug has a real chance of success. Data from clinically annotated PDX models can show that a drug works in tumors like those seen in patients. This makes the story more convincing.
Regulators also review preclinical data before approving a new trial. Clear evidence of activity, along with solid dose and safety data, supports a stronger submission.
It also helps trial sites and doctors feel confident about enrolling patients. Good data can also answer common reviewer questions before they are asked.
Where PDX Models Fall Short
PDX models are powerful, but they have limits. Teams should know these before relying on them.
The mice used in PDX studies have weak immune systems. This means PDX models can’t fully test drugs that work through the immune system. Over time, mouse tissue can also replace parts of the human tumor’s support structure.
PDX studies also take more time and money than cell line work. Rules are changing, too. In 2025, the FDA announced a plan to reduce animal testing for some drugs and encourage new methods like organoids and computer models; these tools can work alongside PDX models. Used together, they give teams the strongest possible data.
How to Choose a PDX Partner
The quality of a PDX study depends on the partner who runs it. Before you begin, ask a few key questions:
- How many models do they offer?
- Are models linked to patient data?
- Do they cover your tumor type?
- Can they run pharmacology studies too?
- How close are they to clinical teams?
A partner with both preclinical and clinical experience can be a big advantage. They understand how lab results translate to patient care. This helps make sure your preclinical data answers the questions that matter most in the clinic.
Turning Better Data Into Better Trials
Oncology trial failures are costly, but many can be avoided. Clinically annotated PDX models and in vivo pharmacology data help teams test drugs on real human tumors before the first patient is dosed. They reveal which drugs work, which patients may benefit, and which doses make sense.
The result is fewer surprises in Phase I and Phase II. Teams can focus their time and money on the drugs with the best chance to help patients.
Ready to strengthen your next oncology program? Connect with our preclinical team to explore PDX studies built to support your path to the clinic.
Check out the rest of our site for more!